{"id":98603,"date":"2023-05-10T00:00:00","date_gmt":"2023-05-10T00:00:00","guid":{"rendered":"https:\/\/medgoo.com\/index.php\/2023\/05\/10\/pharmacologic-therapies-effective-for-excessive-daytime-sleepiness\/"},"modified":"2023-05-12T17:26:17","modified_gmt":"2023-05-12T17:26:17","slug":"pharmacologic-therapies-effective-for-excessive-daytime-sleepiness","status":"publish","type":"post","link":"https:\/\/medgoo.com\/index.php\/2023\/05\/10\/pharmacologic-therapies-effective-for-excessive-daytime-sleepiness\/","title":{"rendered":"Pharmacologic Therapies Effective for Excessive Daytime Sleepiness"},"content":{"rendered":"<h3>\n<p>Solriamfetol, armodafinil-modafinil, and pitolisant reduce daytime sleepiness, with solriamfetol likely superior<\/p>\n<\/h3>\n<p><b>By Elana Gotkine HealthDay Reporter<\/b><\/p>\n<p><b><\/b><\/p>\n<p>WEDNESDAY, May 10, 2023 (HealthDay News) &#8212; For patients with obstructive sleep apnea (OSA), solriamfetol, armodafinil-modafinil, and pitolisant reduce daytime sleepiness, with solriamfetol likely superior, according to a systematic review and meta-analysis published online May 9 in the <em>Annals of Internal Medicine<\/em>.<em><\/em><\/p>\n<p>Tyler Pitre, M.D., from McMaster University in Hamilton, Ontario, Canada, and colleagues compared the effectiveness of drugs for excessive daytime sleepiness (EDS) in OSA in a network meta-analysis of 14 trials with 3,085 patients assigned to any pharmacologic intervention.<\/p>\n<p>The researchers found that solriamfetol improves Epworth Sleepiness Scale (ESS) scores compared with placebo at four weeks (mean difference, \u00e2\u0088\u00923.85; high certainty), while armodafinil-modafinil and pitolisant-H3-autoreceptor blockers probably improve ESS scores (mean differences, \u00e2\u0088\u00922.25 and \u00e2\u0088\u00922.78, respectively; both moderate certainty). Solriamfetol and armodafinil-modafinil improve the Maintenance of Wakefulness Test compared with placebo at four weeks (standardized mean differences, 0.9 and 0.41, respectively; both high certainty), while pitolisant-H3-autoreceptor blockers probably do not (moderate certainty). Armodafinil-modafinil probably increases the risk for discontinuation due to adverse events at four weeks (relative risk, 2.01; moderate certainty), while the association for solriamfetol was not found to be significant.<\/p>\n<p>&#8220;Solriamfetol, armodafinil-modafinil, and pitolisant are effective therapies available to patients with OSA-associated EDS already on conventional therapy,&#8221; the authors write. &#8220;Potential for long-term harm of all available pharmacotherapy remains unclear.&#8221;<\/p>\n<p><a href=\"https:\/\/www.acpjournals.org\/doi\/10.7326\/M22-3473\" target=\"_blank\" rel=\"noopener\">Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n<p><i><\/i><\/p>\n<p><i>Copyright \u00a9 2023 <a href=\"http:\/\/www.healthday.com\/\" target=\"_new\" rel=\"noopener\">HealthDay<\/a>. All rights reserved.<\/i><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Solriamfetol, armodafinil-modafinil, and pitolisant reduce daytime sleepiness, with solriamfetol likely superior<\/p>\n","protected":false},"author":6,"featured_media":98696,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[6],"tags":[11],"class_list":["post-98603","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","tag-news"],"_links":{"self":[{"href":"https:\/\/medgoo.com\/index.php\/wp-json\/wp\/v2\/posts\/98603","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medgoo.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medgoo.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medgoo.com\/index.php\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/medgoo.com\/index.php\/wp-json\/wp\/v2\/comments?post=98603"}],"version-history":[{"count":1,"href":"https:\/\/medgoo.com\/index.php\/wp-json\/wp\/v2\/posts\/98603\/revisions"}],"predecessor-version":[{"id":98695,"href":"https:\/\/medgoo.com\/index.php\/wp-json\/wp\/v2\/posts\/98603\/revisions\/98695"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medgoo.com\/index.php\/wp-json\/wp\/v2\/media\/98696"}],"wp:attachment":[{"href":"https:\/\/medgoo.com\/index.php\/wp-json\/wp\/v2\/media?parent=98603"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medgoo.com\/index.php\/wp-json\/wp\/v2\/categories?post=98603"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medgoo.com\/index.php\/wp-json\/wp\/v2\/tags?post=98603"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}